Invitrogen has created three new business divisions in a move to
strengthen its position in the growing biotechnology industry and
drive growth through improving links between its product
development cycle and customer base.
The production capacity for biopharmaceutical manufacturing will
expand an average of 48 per cent over the next five years for
mammalian and microbial production systems, according to an
Pharmaceutical companies are increasingly looking to retain their
internal focus on research and development (R&D) and marketing
while outsourcing their manufacturing processes, thus fueling a
growing demand for the manufacturing...
Regulatory obstacles to the development of the market for
biogeneric drugs are falling down, and the first products are set
to reach the markets of North America and Europe in 2006-7,
according to consulting firm Frost & Sullivan.
Cambrex has recorded a gain in the second quarter of this year,
with growth in its Bioproducts and Human Health segments. The
performances overshadow the company's troublesome BioPharma
division, indicative of a market for outsourced...
Swiss chemicals firm and contract manufacturer Lonza fulfilled its
promise of stronger financial results in the first half of 2005,
with profits coming in at the lower end of the forecast range, but
still on target, reports Phil Taylor.
A recent study designed to assess biopharmaceutical innovation in
the member states of the Organisation for Economic Cooperation and
Development has found that, in terms of innovation and
biotechnology industry development, Belgium...
According to a recent report, the global bioinformatics market is
currently estimated at about $1.4 billion (€1.1 billion). It is
expected to grow at an average annual growth rate of 15.8 per cent
to reach nearly $3 billion by 2010,...
BioProgress has appointed Richard Trevillion as chief
executive, bolstering its executive management just over a month
after the dosage film specialist issued a trading statement that
sparked a 40 per cent slump in its UK-listed shares,...
As the US Food and Drug Administration continues its deliberations
on generic biopharmaceuticals, the industry body representing
generic drug manufacturers has said that the time has now come for
the agency to make some hard decisions,...
A second market research report has found evidence that production
capacity in the market for contract manufacturing of
biopharmaceuticals is now in excess, in contrast to the hitherto
prevailing wisdom that the sector has been suffering...
Construction of the UK National Biomanufacturing Centre, an
ambitious project aimed at helping biotechnology start-ups get
their product ideas into clinical trials, is progressing on
schedule and should be ready to start production...
US chemicals company Aceto has broken cover and is now racing to
develop a leading player in the market for generic versions of
biologic drugs, even though the regulatory route to approval of
these products is far from established.